Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
GALECTO Aktie jetzt für 0€ handeln | |||||
05.08. | Galecto GAAP EPS of -$2.60 | 2 | Seeking Alpha | ||
05.08. | Galecto, Inc.: Galecto Reports Second Quarter 2025 Operating and Financial Results | 76 | GlobeNewswire (Europe) | BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced... ► Artikel lesen | |
05.08. | Galecto, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
20.06. | Galecto, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
09.05. | Galecto GAAP EPS of -$1.92 | 2 | Seeking Alpha | ||
08.05. | Galecto, Inc. Q1 Loss Declines | - | RTTNews | ||
08.05. | Galecto, Inc.: Galecto Reports First Quarter 2025 Operating and Financial Results | 180 | GlobeNewswire (Europe) | BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced... ► Artikel lesen | |
08.05. | Galecto, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
19.03. | Galecto GAAP EPS of -$18.53 misses by $2.62 | 4 | Seeking Alpha | ||
19.03. | Galecto, Inc.: Galecto Reports Full-Year 2024 Financial Results | 294 | GlobeNewswire (Europe) | Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets... ► Artikel lesen | |
19.03. | Galecto, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 8 | SEC Filings | ||
19.03. | Galecto, Inc. - 10-K, Annual Report | 4 | SEC Filings | ||
01.11.24 | Galecto, Inc.: Galecto Reports Third Quarter 2024 Financial Results | 224 | GlobeNewswire (Europe) | - Completed strategic review to focus on oncology and severe liver diseases - Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 6,000 | +0,03 % | Novo Nordisk Aktie: Turnaround? - CTS Eventim, Evotec, Rheinmetall, RWE und SBO im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
PALATIN TECHNOLOGIES | - | - | Boehringer Ingelheim Limited: Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases | · Collaboration strengthens Boehringer's pipeline in Eye Health.· Many patients with diabetic retinopathy (DR) continue to experience vision loss or treatment fatigue, underscoring an... ► Artikel lesen | |
MAINZ BIOMED | 1,635 | -0,91 % | Mainz Biomed Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
VIKING THERAPEUTICS | 23,050 | -2,39 % | Why Viking Therapeutics Stock Popped Nearly 4% Today | ||
TREVENA | 2,280 | -40,00 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
ABIVAX | 68,70 | -1,43 % | Abivax, CRISPR Therapeutics und Revolution Medicines: Biotech im Höhenflug - das wikifolio ... | ||
GERON | 1,198 | -1,80 % | Geron Corp. Posts Narrower Loss In Q1 | WASHINGTON (dpa-AFX) - Geron Corp. (GERN) posted a first quarter net loss of $19.8 million, or $0.03 per share, compared to a loss of $55.4 million, or $0.09 per share, prior year. Total net... ► Artikel lesen | |
CELLECTAR BIOSCIENCES | 4,670 | -1,37 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update | Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and... ► Artikel lesen | |
GALAPAGOS NV | 27,080 | -2,38 % | Galapagos NV: Galapagos Creates New Subscription Right Plan | Mechelen, Belgium; August 7, 2025, 22.01
CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,800,000 subscription rights under... ► Artikel lesen | |
CARDIFF ONCOLOGY | 1,800 | +0,78 % | Cardiff Oncology, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
CENTOGENE | 0,110 | 0,00 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
SENSEI BIOTHERAPEUTICS | 8,380 | 0,00 % | Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | - Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics... ► Artikel lesen | |
CYTOMX THERAPEUTICS | 1,706 | -3,01 % | CytomX: Wie geht's hier jetzt weiter? | Die Immuntherapie gegen Krebs entwickelt sich stetig weiter, und CytomX Therapeutics gehört zu den Unternehmen, die mit innovativen Ansätzen neue Maßstäbe setzen wollen. Die sogenannte "Probody"-Technologie... ► Artikel lesen | |
CYTOKINETICS | 30,000 | -6,25 % | Cytokinetics, Incorporated: Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025 | ||
FIBROGEN | 12,000 | +7,62 % | FibroGen, Inc.: FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation | Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Market... ► Artikel lesen |